Skip to main navigation

SEARCH

MEDIA

CAREERS

CONTACT

Nektar
  • Our Company
    • Our Story
    • Our Leadership
    • Our Board of Directors
    • Our Partners
    • Locations
    • Contact
  • Our Pipeline
    • Clinical Resources
    • R&D Pipeline
      • Bempegaldesleukin (NKTR-214)
      • Dapirolizumab Pegol (Anti-CD40L)
      • NKTR-358
      • NKTR-262
      • NKTR-255
    • Clinical Trials
    • Expanded Access
    • Investigator Supported Trials
  • Our Medicines
    • U.S. Medicines Marketed by Our Partners
    • EU Medicines Marketed by Our Partners
    • Investigational Medicines
  • Our Science
    • Research Platform
    • Scientific Posters, Presentations and Publications
    • Scientific & Medical Events
  • Investors

    Investor Relations

    • About Us
    • Press Releases
    • Investor Events
    • Stock Information
      • Historic Stock Lookup
    • Analyst Coverage
    • Financials & Filings
      • SEC Filings
    • Corporate Governance
    • Contact IR
    • Email Alerts
  • Media
    • Media Room
    • Video Gallery
    • Image Gallery
  • Careers
    • Overview
    • Life at Nektar
    • Search Jobs
    • Benefits at Nektar
      • Benefits at San Francisco, California
      • Benefits at Huntsville, Alabama
      • Benefits at Hyderabad, India
    • Information for Recruiters

Press Releases

2006 Deutsche Bank Small Cap Growth Conference to Webcast Nektar Corporate Presentation
Feb 10, 2006
Advisory: BIO CEO and Investor Conference to Webcast Nektar Corporate Presentation
Feb 09, 2006
Nektar CEO to Retire; Executive Chairman Appointed Acting CEO
Feb 07, 2006
Merrill Lynch to Webcast Nektar Corporate Presentation
Feb 01, 2006
Pfizer Receives FDA Approval for Exubera, the First Inhaleable Form of Insulin for Controlling Type 1 and Type 2 Diabetes in Adults
Jan 27, 2006
European Commission Approves Exubera(R) (Inhaled Human Insulin) for Treatment of Type 1 and Type 2 Diabetes
Jan 26, 2006
Nektar Therapeutics Appoints New Chief Financial Officer
Jan 19, 2006
Nektar Reports Pfizer to Acquire the Sanofi-Aventis Worldwide Rights to Exubera® (Inhaled Human Insulin)
Jan 13, 2006

Pagination

  • First page « first
  • Previous page ‹ previous
  • …
  • Page 44
  • Page 45
  • Page 46
  • Page 47
  • Page 48
  • Page 49
  • Page 50
  • Page 51
  • Current page 52

Investor Relations

  • About Us
  • Press Releases
  • Investor Events
  • Stock Information
    • Historic Stock Lookup
  • Analyst Coverage
  • Financials & Filings
    • SEC Filings
  • Corporate Governance
  • Contact IR
  • Email Alerts
Nektar

QUICK LINKS

Our Company

Our Pipeline

Our Medicines

Our Science

Investors

Media

Careers

Contact

Privacy

Terms of Use

CONNECT

LOCATIONS

San Francisco, CA

Hyderabad Office

Huntsville, AL

San Francisco Office

Hyderabad, India

Alabama Office
Copyright Nektar © 2023